Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis

An amendment to this paper has been published and can be accessed via the original article.

Source: BMC Nephrology - February 2, 2021 Category: Urology & Nephrology Authors: Anja G äckler, Ulf Schönermarck, Vladimir Dobronravov, Gaetano La Manna, Andrew Denker, Peng Liu, Maria Vinogradova, Sung-Soo Yoon and Manuel Praga Tags: Correction Source Type: research